National Cancer Registry

Definition	A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives	- To measure cancer incidence - To describe cancer by time, place, persons and disease - To provide a national database for further epidemiological research
Case definition	Target cases are: - Incident cases by year of diagnosis - Malignant tumors confirmed by histopathology and/or hematology findings - Cancers of all sites
Sources of data	Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting). 1) The capture system: The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms: - Directly from their clinic; or - Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients 2) The recapture system: The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding	The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3). The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor. The structure is C##.# M####/##, where: - C##.# specifies the primary site - M#### specifies the histology - /## specifies the behavior and the grade of the tumor
Reporting form	NCR reporting form

ATC	Name	B/G	Ingredients	Dosage	Form	Price
C09CA01	COZAAR	B	Losartan potassium - 100mg	100mg	Tablet	1,740,596 L.L
D07CC01	FUCICORT	B	Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g		Cream	376,276 L.L
J07AL02	SYNFLORIX	B	Polysaccharide from each of 10 capsular types of pneumococcus (conjugated to carrier proteins) adsorbed onto aluminium phosphate - 1mcg/0.5ml, Polysaccharide of serotypes 41,2, 18C1,3 and 19F1,4 - 3mcg/0.5ml, 1 adsorbed onto aluminium phosphate - 0.5mg Al3+, 2 conjugated to protein D (derived from NTHi) carrier protein - ~ 13mcg, 3 conjugated to tetanos toxoid carrier protein - ~ 8mcg, 4 conjugated to diphteria toxoid carrier protein - ~ 5mcg		Injectable suspension	4,675,228 L.L
M01AE01	ALGIFAST PEDIATRIC	B	Ibuprofen Lysine - 20mg/ml	20mg/ml	Suspension	393,746 L.L
A07BC05	SMECTALIA STRAWBERRY	B	Diosmectite - 3g/sachet	3g/sachet	Powder for suspension	935,570 L.L
B01AX05	ARIXTRA	B	Fondaparinux sodium - 7.5mg/0.6ml	7.5mg/0.6ml	Injectable solution	12,004,668 L.L
D07CC01	FUCICORT	B	Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g		Cream	501,253 L.L
L01EF01	IBRANCE	B	Palbociclib - 125mg	125mg	Capsule	172,164,216 L.L
M01AE01	ADVIL LIQUI-GELS EXTRA STRENGTH	B	Ibuprofen - 400mg	400mg	Capsule	575,165 L.L
R06AX13	CLARITINE	B	Loratadine (micronised) - 5mg/5ml	5mg/5ml	Syrup	430,030 L.L
A07DA03	IMODIUM	B	Loperamide HCl - 2mg	2mg	Capsule	138,416 L.L
B02AA02	EXACYL	B	Tranexamic acid - 500mg/5ml	500mg/5ml	Injectable solution	748,520 L.L
J07AL02	PREVENAR 20	B	Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F,8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F,22F, 23F, 33F (2.2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein (approximately 51mcg) adsorbed on aluminium phosphate (0.125mg aluminium) -		Injectable suspension	7,415,107 L.L
L01EF01	IBRANCE	B	Palbociclib - 125mg	125mg	Tablet, film coated	172,164,216 L.L
C09CA03	DIOVAN	B	Valsartan - 80mg	80mg	Tablet, film coated	602,041 L.L
J07AL02	VAXNEUVANCE	B	Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 22F, 23F,33F (2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg) Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate adjuvant -		Injectable suspension	6,988,413 L.L
N02AJ13	ZALDIAR	B	Paracetamol - 325mg, Tramadol - 37.5mg		Tablet, film coated	404,497 L.L
N03AX18	VIMPAT	B	Lacosamide - 50mg	50mg	Tablet, film coated	1,024,008 L.L
R01BA53	AURIMEL	B	Phenylephrine HCl - 5mg/5ml, Sodium citrate - 325mg/5ml, Carbinoxamine maleate - 2mg/5ml, Dextromethorphan HBr - 5mg/5ml		Syrup	319,963 L.L
L01DB01	CAELYX	B	Doxorubicin HCl pegylated liposomes - 20mg/10ml	20mg/10ml	Injectable concentrated solution	L.L
A07DA03	IMODIUM INSTANTS	B	Loperamide HCl - 2mg	2mg	Tablet, orodispersible	451,531 L.L
A10BJ06	OZEMPIC	B	Semaglutide - 0.25mg	0.25mg	Injectable solution	10,927,526 L.L
B02BA01	KONAKION MM PEDIATRIC	B	Phytomenadione - 2mg/0.2ml	2mg/0.2ml	Solution	442,124 L.L
J07AP03	TYPHIM VI	B	Salmonella typhi polysaccharides - 0.025mg/0.5ml	0.025mg/0.5ml	Injectable solution	1,118,077 L.L
R06AX22	EBASTEL	B	Ebastine - 10mg	10mg	Tablet, film coated	722,987 L.L
A10BJ06	OZEMPIC	B	Semaglutide - 0.5mg	0.5mg	Injectable solution	10,927,526 L.L
J07AP03	TYPHIBEV TYPHOID CONJUGATED VACCINE (MONOVALENT)	B	Salmonella typhi polysaccharides Vi purified - 25mcg of Vi-PS2/0.5ml		Injectable suspension	4,020,777 L.L
M01AE02	PROXEN 500	B	Naproxen - 500mg	500mg	Tablet, film coated	841,245 L.L
N03AX18	VIMPAT	B	Lacosamide - 100mg	100mg	Tablet, film coated	7,835,296 L.L
R02A	MAXILASE MAUX DE GORGE	B	Alpha-Amylase - 200U.CEIP/ml	200U.CEIP/ml	Syrup	342,680 L.L

National Cancer Registry (NCR)